The CARVIVA HF trial- Is the devil in the detail?

Volterrani and colleagues [1] published a prospective, randomised, blinded study in patients with heart failure (HF). They studied patients exercise capacity at baseline and after carvedilol monotherapy, ivabradine monotherapy or dual therapy. They used the 6-min walk test (6MWT) and VO2 peak as their primary end-points along with modalities such as echo, NYHA classification and quality of life. They have concluded that ivabradine and dual therapy improve exercise capacity and quality of life in HF patients.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Letter to the editor Source Type: research